Medical University of Warsaw
Warsaw, Poland

The Medical University of Warsaw was founded in January 1950, building on the University of Warsaw's former Faculty of Medicine, which had been established in the early nineteenth century. The Medical University of Warsaw is the largest medical school in Poland, and one of the most prestigious. Wikipedia.

Time filter

Source Type

Medical University of Warsaw and Instytut Farmaceutyczny | Date: 2017-02-01

The present invention relates to the antipsoriatic emulsion composition, especially in the form of a cream, comprising an effective therapeutic dose of cefazolin, the ingredients of the oil phase and the ingredients of the water phase, characterized by that(i) the ingredients of the oil phase include:- liquid paraffin or white petrolatum,- polyoxyethylene stearyl ether (21), and- cetostearyl alcohol;(ii) the ingredients of the oil phase include a buffer solution to maintain the pH value of the initial composition from 5 to 9, preferably in the range 6 - 8,(iii) optionally, comprising an additional amphiphilic nonionic emulsifier, and other soluble/water miscible excipients,wherein water content accounts for 50 to 80% by weight of the composition.

Medical University of Warsaw | Date: 2017-05-24

Disclosed herein is a ring prepared from osteoinductive and/or osteogenic material for a use in a dental and orthognathic surgery in case of bone surface deficiency for the introduction of intraosseous dental implants.

The present invention relates to a prooxidant synergistic combination to treat B-cell malignancies, such as B cell lymphomas, which comprises a thioredoxin reductase inhibitor, selected from a group comprising auranofin and SK053, and L- or D-ascorbate. The combination of the invention exerts synergistic cytotoxic effects towards malignant, but not normal B cells.

Medical University of Warsaw | Date: 2015-07-15

Disclosed herein is a ring prepared from osteoinductive and/or osteogenic material for a use in a dental and orthognathic surgery in case of bone surface deficiency for the introduction of intraosseous dental implants.

Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue to increase in diameter before they eventually rupture. Left untreated, the patients prognosis is dismal, since the internal bleeding of the rupture brings about sudden death. Although successful treatment cures the disease, the risky procedures can result in paraplegia from spinal cord ischaemia or even death, particularly for aneurysms extending from the thoracic to the abdominal aorta and thus involving many segmental arteries to the spinal cord, i.e. thoracoabdominal aortic aneurysms of Crawford type II. Although various strategies have achieved a remarkable decrease in the incidence of paraplegia, it is still no less than 10 to 20%. However, it has been found that the deliberate occlusion of the segmental arteries to the paraspinous collateral network finally supplying the spinal cord does not increase rates of permanent paraplegia. A therapeutic option, minimally invasive segmental artery coil embolization has been devised which proceeds in a staged way to occlude groups of arteries under highly controlled conditions after which time must be allowed for arteriogenesis to build a robust collateral blood supply. PAPA-ARTiS is a phase II trial to demonstrate that a staged treatment approach can reduce paraplegia and mortality dramatically. It can be expected to have both a dramatic impact on the individual patients quality of life if saved from a wheelchair, and also upon financial systems through savings in; 1) lower costs in EU health care; 2) lower pay-outs in disability insurance (est. at 500k in Year 1), and; 3) loss of economic output from unemployment. Approx. 2500 patients a year in Europe undergo these high risk operations with a cumulative paraplegia rate of over 15%; therefore >100M per year in costs can be avoided and significantly more considering the expected elimination of type II endoleaks.

Agency: European Commission | Branch: H2020 | Program: CSA | Phase: H2020-TWINN-2015 | Award Amount: 1.19M | Year: 2016

In 2013, the Science magazine announced Immunotherapy of cancer as the Breakthrough of the Year. The results of ongoing clinical studies with new cancer immunotherapeutics strongly support this enthusiasm. Following the lead of the top research groups, the Coordinator of the present proposal, Medical University of Warsaw (MUW) displays a predominant ambition of becoming a major player in the thriving area of Immuno-Oncology. MUW is one of the leading centres of competence in the Oncology field in Poland and presents a robust desire for further improvement of its excellence merits. Therefore, the main concept of the STREAM proposal is to bring together the high-level European research organizations with synergistic scientific and innovative expertise in the field of Immuno-Oncology, in order to establish an international, long-term, strategic partnership with MUW. The main model of the STREAM proposal is to foster enhanced scientific dialogue and twinning between MUW and four outstanding research centres via trans-national visits of scientific personnel, joint organization of a summer school and workshops, as well as promoting the active participation of STREAM researchers in the prestigious scientific conferences. Within the duration of the current project we intend to significantly enrich MUWs, regional and national quality profile regarding all of the variables of Composite indicator of Research Excellence in the Immuno-Oncology area. We will also set a new standard for conducting bioresearch and innovative thinking in Poland. We expect that the scale, ambition, and innovative character of the proposed project will bring the MUWs excellence to a new level - internationally recognized and competitive, in order to contribute to the well-being of the society and knowledge-based economy of Poland and EU. Our proposal provides an exceptional occasion to achieve real impact on human health, quality of life and economic status in the new area of enlarged Europe.

Szablewski L.,Medical University of Warsaw
Biochimica et Biophysica Acta - Reviews on Cancer | Year: 2013

It has been known for 80. years that cancer cell growth in an energy-related process supported by an increased glucose metabolism. This phenomenon suggests a need for a corresponding increased uptake of glucose across the plasma membrane through an enhancement in the glucose transporter proteins, SGLT proteins as well as GLUT proteins. The results of many studies have demonstrated that the expression of glucose transporters, especially GLUT1, is increased in a variety of malignancies. GLUT1 overexpression has been found to be associated with tumor progression. It was found that GLUT1 overexpression is associated with poor overall survival in various malignant tumors. © 2012 Elsevier B.V.

The object of the invention is an endoscope needle guide (11) for performance of injections at an angle into the walls of tubular organs to the predetermined depth, comprising a tubular member (1) with a first end (2) and a second end (3),wherein the tubular member (1) has at least one longitudinal aperture (4) on its surface, parallel to the longitudinal axis of the tubular member (1), and an apparatus for performance of injections at an angle into the walls of tubular organs to the predetermined depth comprising an endoscope (17) and a guide (11).

The method, characterized in that, the powdered chitosan is dissolved in water to obtain a 5% solution, into which a 70-90% acetic acid is added and after the formation of the blank intramedullary nail and carrying a coagulating bath and neutralization bath it is subjected to a crosslinking bath in a solution formed from 0.5 to 2% of sodium tri-polyphosphate and 0.5% to 3% Na_(3)PO_(4) for 24 to 48 hours in temperature of 50C to 140C and then it is subjected to the drying process, for a period of 6 to 10 days, and finally the surface of the blank is treated to form the intramedullary nail. The surface treatment is carried out until the surface of the intramedullary nail contains at least 20% - 40% of the pore of the depth of 0.1mm to 1mm.

Medical University of Warsaw, Instytut Farmaceutyczny and Instytut Biochemii I Biofizyki Polskiej Akademii Nauk | Date: 2016-10-12

The subject invention relates to agents for use in treatment and/or prevention of Alzheimers disease. The group of agents include horse chestnut extract, escins, their salts and derivatives.

Loading Medical University of Warsaw collaborators
Loading Medical University of Warsaw collaborators